Litfulo is used to treat severe alopecia areata to reduce hair loss in adults and adolescents 12 years and older. It is an oral capsule that is taken once a day. Includes Litfulo FDA approval, mechanism, and dosing information., Medication Guide Indication Patient Site LITFULO™ (ritlecitinib) The first and only FDA-approved treatment for severe alopecia areata in both adults and adolescents as young as 12.1-4, FAQ – LITFULO (Ritlecitnib) What is LITFULO? LITFULO (Ritlecitnib) is a selective dual Janus kinase 3 (JAK3) and tyrosine protein (TEC) kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for adults and adolescents 12 years and older with severe alopecia areata (AA) (1). The FDA approved LITFULO for AA in June 2023., Find patient medical information for Litfulo (ritlecitinib) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings, LITFULO (ritlecitinib) capsules are formulated with ritlecitinib tosylate, a kinase inhibitor. Ritlecitinib tosylate is a white to off white to pale pink solid which is freely soluble in water., LITFULO ® What is LITFULO? (ritlecitinib) What is LITFULO? LITFULO is a prescription medicine that is a kinase inhibitor. LITFULO is used to treat an immune system problem that causes severe hair loss (alopecia areata) in adults and children 12 years and older. It is not known if LITFULO is safe and effective in children under 12 years of age..